You've probably heard of blood thinners. They are among the most common prescriptions in the world, taken daily by millions to lower the risk of a stroke. But one group of patients has long been left in a gray zone.
A new study of 1,502 people with atrial fibrillation and a prior brain bleed found that patients taking newer blood thinners had sharply lower rates of stroke and death. Crucially, there was no sign of a higher risk of a second bleed.
The research was published October 21, 2026, in Neurology, the medical journal of the American Academy of Neurology.
The clinical dilemma that has stalled treatment
AFib, short for atrial fibrillation, is an irregular heartbeat that lets blood pool in the heart and form clots. Doctors routinely prescribe blood thinners to lower that risk.
Also read: Air pollution may be quietly raising your blood sugar even if you don't have diabetes
But a previous intracranial hemorrhage, bleeding inside the skull, flips the calculus. The same drugs that keep clots from forming can also deepen a bleed.
What the Finnish team found at one year
The participants, average age 78, had suffered a brain bleed at least four months before their AFib was diagnosed. Researchers at the University of Helsinki followed them for up to two years.
Fifteen percent received newer blood thinners known as direct oral anticoagulants. That group of drugs includes apixaban, rivaroxaban, edoxaban and dabigatran. Twenty-nine percent took the older drug warfarin. The remaining 56 percent took no blood thinner at all.
After one year, patients on the newer drugs had an 83 percent lower risk of an ischemic stroke, a stroke caused by a clot, than those on no treatment. Their risk of dying was 80 percent lower. Their rate of a new brain bleed was no higher.
Also read: Two drugs you may have in your medicine cabinet just entered an Alzheimer's trial
Warfarin cut stroke risk by about half. But it was tied to an 85 percent higher chance of another brain bleed.
"Importantly, our study found newer anticoagulants were not associated with another brain bleed, while warfarin was," said Paula Tiili, MD, of the University of Helsinki.
The caveats behind the headline numbers
Because the study was observational, the authors say the findings show an association, not that the drugs caused the different outcomes. They also excluded patients who died or had a stroke within three months of their AFib diagnosis.
That means the results apply to people who had already stabilized past the earliest, highest-risk window.
Also read: 7 warning signs your vitamin D may be dropping as the days get shorter
Current US guidance already favors the newer drugs over warfarin on bleeding risk.
The 2023 cardiology guideline from the American Heart Association addresses patients with AFib and a spontaneous brain bleed. It notes that restarting anticoagulation around seven to eight weeks later may be considered on a case by case basis.
Patients who stopped a blood thinner after a bleed, or were told they could not take one, can bring the new Neurology findings to their next cardiology or neurology appointment. They should not change anything on their own.
Also read: 1 in 5 infants globally missed their first measles vaccine in 2023, and cases are up 40% since 2019
Also read: No approved drug exists for cocaine addiction, and the NIH just bet on a psychedelic
This article is made and published by Aksel Kryhlmand, who may have used AI in the preparation.